Dianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is anticipated to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.86 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Trading Down 5.6 %

DNTH stock opened at $20.74 on Wednesday. The stock has a 50-day moving average price of $22.34 and a 200-day moving average price of $24.70. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77. The firm has a market cap of $613.84 million, a PE ratio of -8.30 and a beta of 1.82.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research analyst reports. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim restated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average target price of $52.14.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.